Interleukin Genetics' founder returns to CEO slot

Interleukin Genetics says CEO Lewis Bender has resigned to pursue "other business opportunities." Mass High Tech reports that founder Kenneth Kornman, who is currently president and chief scientific officer, will take the CEO slot, too. Bender started running the company back in 2008 and it has struggled, as the article notes, as sales for genetic tests have plunged. There may not be enough time left for Interleukin, which said it had about $3.8 million in cash and equivalents on hand, to last through November 30. A longer future is possible, the company said, if it can get a credit facility extended. Interleukin develops genetic tests for chronic conditions. Story

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.